Clinical Trials Logo

Stage 5 Chronic Kidney Disease clinical trials

View clinical trials related to Stage 5 Chronic Kidney Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02392299 Completed - Clinical trials for Stage 5 Chronic Kidney Disease

Risk of Falling in Chronic Kidney Disease 5

Start date: September 2015
Phase:
Study type: Observational

The purpose of this study is to explore the relative importance of the frailty and cardiovascular function as potential exercise-modifiable risk factors for falling in patients receiving haemodialysis.

NCT ID: NCT02392208 Completed - Clinical trials for End-Stage Renal Disease

Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5

Start date: July 2015
Phase: Phase 4
Study type: Interventional

Chronic Kidney Disease Stage 5 (CKD5) patients receiving maintenance hemodialysis are at an increased risk for developing bloodstream infections. Vancomycin is traditionally used as first-line therapy for treating these infections, but the emergence of less-susceptible bacterial strains necessitates the consideration of alternative antibiotic therapy. Telavancin is a new antibiotic that has broad-spectrum antimicrobial activity against gram-positive bacteria, including vancomycin-intermediate staphylococcus aureus. While dosing recommendations for telavancin are available for patients with normal kidney function, there are no published recommendations for CKD5 patients receiving hemodialysis. A pharmacokinetic study is needed to characterize the pharmacokinetic parameters of telavancin in these patients to determine the extent of drug removal by hemodialysis and to establish dosing recommendations for CKD5 patients on maintenance hemodialysis.